Divalproex sodium: migraine treatment and monitoring.
Divalproex sodium is an effective drug for the treatment of migraine. Most adverse drug events are transient and not of great clinical concern. Although rare, well-documented examples of liver toxicity have been reported in children under 2 years of age on polypharmacy. Additional cases occur in children under 10 who are receiving polypharmacy, particularly those who have intractable seizures and degenerative central nervous system disease. Clinicians who treat migraineurs with divalproex sodium do not need to be overly preoccupied with monitoring of drug levels and liver function tests. The most valuable test is clinical observation of the patient.
Silberstein
S D
SD
Temple University School of Medicine, Philadelphia, Penn, USA.
Wilmore
L J
LJ
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008099:Liver / Q000187:drug effects*; D008111:Liver Function Tests; D008881:Migraine Disorders / Q000188:drug therapy*; D012307:Risk Factors; D014635:Valproic Acid / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use / Q000652:urine
D014635:Valproic Acid